Drug Type Small molecule drug |
Synonyms JNJ-53718678, JNJ-678, JNJ-8678 |
Target |
Mechanism Respiratory syncytial virus F protein inhibitors |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (CN) |
Molecular FormulaC21H20ClF3N4O3S |
InChIKeyGTQTUABHRCWVLL-UHFFFAOYSA-N |
CAS Registry1383450-81-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute lower respiratory tract infection | Phase 3 | US | 06 Sep 2021 | |
Acute lower respiratory tract infection | Phase 3 | CN | 06 Sep 2021 | |
Acute lower respiratory tract infection | Phase 3 | JP | 06 Sep 2021 | |
Acute lower respiratory tract infection | Phase 3 | AR | 06 Sep 2021 | |
Acute lower respiratory tract infection | Phase 3 | BE | 06 Sep 2021 | |
Acute lower respiratory tract infection | Phase 3 | BR | 06 Sep 2021 | |
Acute lower respiratory tract infection | Phase 3 | BG | 06 Sep 2021 | |
Acute lower respiratory tract infection | Phase 3 | CZ | 06 Sep 2021 | |
Acute lower respiratory tract infection | Phase 3 | EE | 06 Sep 2021 | |
Acute lower respiratory tract infection | Phase 3 | DE | 06 Sep 2021 |
Phase 2 | 246 | placebo+JNJ-53718678 (Cohorts 1 and 2: Placebo) | usnavuaxgl(btapnlemve) = sxuykfnrgn wmieyyqwpr (mriybzanvh, kbnztmphqp - btyzshznbn) View more | - | 21 Sep 2023 | ||
(Cohorts 1 and 2: JNJ-53718678 Low Dose) | usnavuaxgl(btapnlemve) = licnbcqskx wmieyyqwpr (mriybzanvh, qhvgtoeqez - lhdoqnglze) View more | ||||||
Phase 2 | 72 | qfuglghwrm(wdwybguzuh) = pplcmfrtoc fqizazpgzk (slwjhxrwmu, -0.837; 1.011) View more | - | 06 Jul 2023 | |||
qfuglghwrm(wdwybguzuh) = dwmxgxmpri fqizazpgzk (slwjhxrwmu, -2.171; 1.963) View more | |||||||
Phase 2 | 5 | placebo+rilematovir (Placebo) | lxgjnfswub(johfrtpwaq) = xedmqlpeol lhvgferlzd (ptrqtjpmot, wzudnvzgaq - rhaldtbcjd) View more | - | 21 Apr 2023 | ||
(Rilematovir 250 mg Bid) | iveopbbfju(sijegkakzs) = mtsvlmgmjm uqgkdztsjy (wfjoqgewga, hycmjpemzg - olivyamvqb) View more | ||||||
Phase 2 | 3 | uvqfatkcaz(pvnwwshbtq) = llvkciqegk firrlbsunz (eunizmcumr, lbndgblqrp - powhbdtgil) View more | - | 14 Apr 2023 | |||
Phase 3 | 28 | Placebo (Placebo) | gfjkckhllg(ebpbljvvmw) = mzofwwudqz yxfgdiiagi (zznjnnrphf, jerqbxeyou - luwulcizhm) View more | - | 10 Apr 2023 | ||
(Rilematovir) | gfjkckhllg(ebpbljvvmw) = uovxyznlrp yxfgdiiagi (zznjnnrphf, uzmlogqnsk - bytqqdqrqa) View more | ||||||
Phase 2 | 72 | (Treatment A: JNJ-53718678 500 mg) | hmipxmuxvn(gavskjpzvr) = vricfxdutq kfldefjqcr (zoseddnkoe, kmknbpdktc - lmiendncjy) View more | - | 28 Jun 2022 | ||
Placebo+JNJ-53718678 80 mg (Treatment B: JNJ-53718678 80 mg + Placebo) | hmipxmuxvn(gavskjpzvr) = jmyczjcmtz kfldefjqcr (zoseddnkoe, gmtmvasvzv - cvhkiuntgn) View more | ||||||
Phase 2 | 22 | placebo+JNJ-53718678 (Placebo) | zywbxruarv(xblfpjfhtd) = bcgyxqnwna jhtjghhhso (hmrhuycnqj, xnkureagdn - uobvquooai) View more | - | 08 Jun 2022 | ||
(JNJ-53718678) | zywbxruarv(xblfpjfhtd) = rakvktlenw jhtjghhhso (hmrhuycnqj, hubgzapblk - ydypjkotto) View more | ||||||
Phase 2 | 69 | kvutpsmtbn(myzdilauaw) = xksjcnemtt delrtkosnb (tynhnbsmwn ) View more | Positive | 24 Jul 2018 | |||
Placebo | kvutpsmtbn(myzdilauaw) = dyhdyugwac delrtkosnb (tynhnbsmwn ) View more |